These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30284558)

  • 1. [Edoxaban in patients with atrial fibrillation and cancer].
    Maurea N; Riva L
    G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):13S-19S. PubMed ID: 30284558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
    Wang K; Li H; Kwong WJ; Antman EM; Ruff CT; Giugliano RP; Cohen DJ; Magnuson EA;
    J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial.
    Xu H; Ruff CT; Giugliano RP; Murphy SA; Nordio F; Patel I; Shi M; Mercuri M; Antman EM; Braunwald E
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation.
    Bergmark BA; Park JG; Hamershock RA; Melloni GEM; De Caterina R; Antman EM; Ruff CT; Rutman H; Mercuri MF; Lanz HJ; Braunwald E; Giugliano RP
    Circ Cardiovasc Qual Outcomes; 2024 Jul; 17(7):e010561. PubMed ID: 38828563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
    Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial.
    Nicolau AM; Corbalan R; Nicolau JC; Ruff CT; Zierhut W; Kerschnitzki M; Duris T; Juul-Möller S; Voitk J; Trevisan M; Nordio F; Antman EM; Giugliano RP
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):167-175. PubMed ID: 31687762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial.
    Magnuson EA; Vilain K; Wang K; Li H; Kwong WJ; Antman EM; Ruff CT; Giugliano RP; Cohen DJ;
    Am Heart J; 2015 Dec; 170(6):1140-50. PubMed ID: 26678636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
    Minguet J; Sims HM; Smith KH; Bramlage P
    Expert Rev Clin Pharmacol; 2017 Jan; 10(1):5-15. PubMed ID: 27817212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation.
    Weitz JI; Connolly SJ; Patel I; Salazar D; Rohatagi S; Mendell J; Kastrissios H; Jin J; Kunitada S
    Thromb Haemost; 2010 Sep; 104(3):633-41. PubMed ID: 20694273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Edoxaban: A direct oral anticoagulant.
    Poulakos M; Walker JN; Baig U; David T
    Am J Health Syst Pharm; 2017 Feb; 74(3):117-129. PubMed ID: 28122753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves.
    Carnicelli AP; De Caterina R; Halperin JL; Renda G; Ruff CT; Trevisan M; Nordio F; Mercuri MF; Antman E; Giugliano RP;
    Circulation; 2017 Mar; 135(13):1273-1275. PubMed ID: 28209729
    [No Abstract]   [Full Text] [Related]  

  • 12. Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction).
    Aisenberg J; Chatterjee-Murphy P; Friedman Flack K; Weitz JI; Ruff CT; Nordio F; Mercuri MF; Choi Y; Antman EM; Braunwald E; Giugliano RP
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e003998. PubMed ID: 29748353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48).
    Ruff CT; Giugliano RP; Antman EM; Crugnale SE; Bocanegra T; Mercuri M; Hanyok J; Patel I; Shi M; Salazar D; McCabe CH; Braunwald E
    Am Heart J; 2010 Oct; 160(4):635-41. PubMed ID: 20934556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial.
    Vilain K; Li H; Kwong WJ; Antman EM; Ruff CT; Braunwald E; Cohen DJ; Giugliano RP; Magnuson EA;
    Circ Cardiovasc Qual Outcomes; 2020 Nov; 13(11):e006511. PubMed ID: 33148013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial.
    Kato ET; Giugliano RP; Ruff CT; Koretsune Y; Yamashita T; Kiss RG; Nordio F; Murphy SA; Kimura T; Jin J; Lanz H; Mercuri M; Braunwald E; Antman EM
    J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27207971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial.
    Steffel J; Ruff CT; Braunwald E; Hamershock RA; Murphy SA; Nieminen M; Lanz HJ; Mercuri MF; Peterson N; Antman EM; Giugliano RP
    Europace; 2019 Feb; 21(2):306-312. PubMed ID: 30462220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trial.
    Eisen A; Giugliano RP; Ruff CT; Nordio F; Gogia HS; Awasty VR; Henderson DA; Mercuri MF; Rutman H; Antman EM; Braunwald E
    Am Heart J; 2016 Feb; 172():144-51. PubMed ID: 26856226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation.
    Okumura K; Akao M; Yoshida T; Kawata M; Okazaki O; Akashi S; Eshima K; Tanizawa K; Fukuzawa M; Hayashi T; Akishita M; Lip GYH; Yamashita T;
    N Engl J Med; 2020 Oct; 383(18):1735-1745. PubMed ID: 32865374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial.
    Bergmark BA; Kamphuisen PW; Wiviott SD; Ruff CT; Antman EM; Nordio F; Kuder JF; Mercuri MF; Lanz HJ; Braunwald E; Giugliano RP
    Circulation; 2019 Nov; 140(22):1792-1801. PubMed ID: 31597460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
    Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
    Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.